# A High-Density Admixture Map for Disease Gene Discovery in African Americans

Michael W. Smith, <sup>1,2</sup> Nick Patterson, <sup>3</sup> James A. Lautenberger, <sup>1</sup> Ann L. Truelove, <sup>1,2</sup> Gavin J. McDonald, <sup>3,4</sup> Alicja Waliszewska, <sup>3,5,6</sup> Bailey D. Kessing, <sup>1,2</sup> Michael J. Malasky, <sup>1,2</sup> Charles Scafe, <sup>10</sup> Ernest Le, <sup>3</sup> Philip L. De Jager, <sup>3,5,6</sup> Andre A. Mignault, <sup>4</sup> Zeng Yi, <sup>11</sup> Guy de Thé, <sup>12</sup> Myron Essex, <sup>7</sup> Jean-Louis Sankalé, <sup>7</sup> Jason H. Moore, <sup>13,14</sup> Kwabena Poku, <sup>16</sup> John P. Phair, <sup>17</sup> James J. Goedert, <sup>18</sup> David Vlahov, <sup>19</sup> Scott M. Williams, <sup>13,14,15</sup> Sarah A. Tishkoff, <sup>20</sup> Cheryl A. Winkler, <sup>1,2</sup> Francisco M. De La Vega, <sup>10</sup> Trevor Woodage, <sup>10</sup> John J. Sninsky, <sup>21</sup> David A. Hafler, <sup>3,5,6</sup> David Altshuler, <sup>3,4,8,9</sup> Dennis A. Gilbert, <sup>10</sup> Stephen J. O'Brien, <sup>1</sup> and David Reich<sup>3,4</sup>

¹Laboratory of Genomic Diversity, National Cancer Institute, and ²Basic Research Program, Science Applications International Corporation, National Cancer Institute, Frederick, MD; ³Program in Medical and Population Genetics, Broad Institute, Cambridge, MA; ⁴Department of Genetics and ⁵Laboratory of Molecular Immunology, Harvard Medical School, ⁵Center for Neurologic Disease, Brigham and Women's Hospital, ²Harvard AIDS Institute and Department of Immunology and Infectious Diseases, Harvard School of Public Health, and Departments of ³Medicine and ³Molecular Biology, Massachusetts General Hospital, Boston; ¹¹Oapplied Biosystems, Foster City, CA; ¹¹Institute of Virology, Chinese Academy of Preventive Medicine, Beijing; ¹²Department of Viral Oncology-Epidemiology, Institut Pasteur, Centre National de la Recherche Scientifique, Paris; ¹³Department of Molecular Physiology and Biophysics, ¹⁴Center for Human Genetics Research, and ¹⁵Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN; ¹⁶School of Administration, University of Ghana, Legon, Ghana; ¹⁻Howard Brown Health Center and Department of Medicine, Northwestern University, Chicago; ¹⁶Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD; ¹⁶Center for Urban Epidemiologic Studies, New York Academy of Medicine, New York; ²⁶Department of Biology, University of Maryland, College Park, MD; and ²¹Celera Diagnostics, Alameda, CA

# Introduction

Admixture mapping (also known as "mapping by admixture linkage disequilibrium," or MALD) offers an approach for performing a whole-genome linkage disequilibrium (LD)-based association scan at a fraction of the cost of haplotype or direct association mapping (Chakraborty and Weiss 1988; Risch 1992; Briscoe et

Received January 26, 2004; accepted for publication March 3, 2004; electronically published April 14, 2004.

Address for correspondence and reprints: Dr. David Reich, Department of Genetics, Harvard Medical School, New Research Building, 77 Avenue Louis Pasteur, Boston, MA 02115. E-mail: reich@receptor.med.harvard.edu

 $\ \, \odot$  2004 by The American Society of Human Genetics. All rights reserved. 0002-9297/2004/7405-0019\$15.00

al. 1994; Stephens et al. 1994; McKeigue 1997, 1998; Zheng and Elston 1999; McKeigue et al. 2000; Lautenberger et al. 2000; Pfaff et al. 2001; Smith et al. 2001; Halder and Shriver 2003; Hoggart et al. 2003). The idea of admixture mapping is to screen along the genome in patients such as African Americans or Hispanic Americans, whose genomes have chromosomal segments of different origins because of historic gene flow between different ethnic groups (e.g., African, European, and American Indian). The strategy is to identify a genomic region with an unusually high contribution of ancestry from one ancestral population, usually the population with the highest incidence of disease. Admixture mapping is expected to be particularly powerful for finding genes for diseases that differ strikingly in frequency

Table 1			
Sources for SNPs	Used To	Build the	е Мар

	No. of SNPs in		
Source <sup>a</sup>	Entire Database	Validated Map of 3,011	Reduced Map of 2,154
TaqMan Assays-On-Demand SNP Genotyping Products database (De La Vega et al. 2002)	177,781	1,913	1,316
The SNP Consortium Allele Frequency Project (SNP Consortium Web site)	54,824	759	592
Applera Genomics Initiative exon resequencing database (Adams et al. 2002) <sup>b</sup>	266,135	304	219
Previously identified as informative for admixture analysis (Parra et al. 1998)	18	14	13
SNPs culled by D.R. from random published sources (especially Reich et al. 2003) and unpublished data	1,348	14	9
SeattleSNPs discovered by resequencing genes (UW-FHCRC Variation Discovery Resource Web site)	6,305	7	5
Total <sup>b</sup>	~450,000	3,011	2,154

<sup>&</sup>lt;sup>a</sup> Many SNPs had allele frequency information submitted from multiple sources. To create a nonredundant entry, we included frequency data only from the source in which the most samples were genotyped.

across populations, because of the possibility that there may be genetic loci that underlie these differences. For example, multiple sclerosis is a good candidate for admixture mapping, because it is heritable and has a much higher genetic risk in European than African Americans (Kurtzke et al. 1979), and prostate cancer and end-stage renal disease are good candidates because their incidences are higher in people of African descent (Klag et al. 1997; Davey Smith et al. 1998).

The key advantage of admixture mapping is that it requires the study of substantially fewer genetic markers than do other methods of association mapping (haplotype or direct association studies). Because of the recent admixture of African Americans (within the last 20 generations), their genomes have not been shuffled much by recombination since population mixing began, and the stretches of identical ancestry should be many megabases in extent. As a result, although  $10^5-10^6$  markers may be necessary for whole-genome haplotype studies (Gabriel et al. 2002; Carlson et al. 2003), a couple thousand MALD markers typed in an admixed population cohort should be adequate to assess ancestry information genomewide.

Admixture mapping has not yet been successfully used to identify a disease gene, although theoretical and empirical studies of feasibility are encouraging (Chakraborty and Weiss 1988; Risch 1992; Briscoe et al. 1994; Stephens et al. 1994; McKeigue 1997, 1998; Zheng and Elston 1999; Lautenberger et al. 2000; McKeigue et al. 2000; Pfaff et al. 2001; Smith et al. 2001; Halder and Shriver 2003; Hoggart et al. 2003; Rosenberg et al. 2003; Patterson et al. 2004 [in this issue]). A major reason for the lack of results so far is that there has been limited availability of highly informative MALD markers—that is, those with known large differences in allele frequencies across major ethnic groups. Recently, the genotyping of

hundreds of thousands of SNPs from several populations has improved the prospects for admixture mapping. Here we describe a high-density map of 3,011 SNPs, <1% of the screening database, that have been validated in a second and independent set of samples. In the accompanying article (Patterson et al. 2004 [in this issue]), we present methods that efficiently combine the information from neighboring, partially informative markers, to make estimates of ancestry that are suitable for disease gene discovery. The highly differentiated markers validated in this study, as well as the new methods, should facilitate admixture mapping as a powerful method for disease gene localization.

#### Methods

Building a Large Database of SNPs from Which to Choose an Admixture Map

The key resource for building an admixture map in African Americans is a very large database of genetic variants for which allele frequencies are known in populations of both European and African descent (table 1). Although most genetic variants have similar frequencies in these ancestral populations (Lewontin 1972; Nei and Roychoudhury 1982), a small fraction have large enough differences to be useful for admixture mapping.

We combined SNPs from public and private databases to obtain a list of nonredundant markers with frequencies known in populations of both European and African descent (table 1). For each SNP, we recorded the frequencies, number of samples genotyped, physical position in the HG16 public genome assembly, and genetic position in the deCODE map (Kong et al. 2002). We eliminated SNPs from analysis if they appeared to have

<sup>&</sup>lt;sup>b</sup> Only 10,530 SNPs from the Applera gene resequencing database, those with SIC >0.1, were in the actual list from which SNPs were selected. This meant that the total number of SNPs in the list we analyzed was 250,806; however, the effective number used for choosing differentiated markers was thus larger, ~450,000.

discrepant physical and genetic positions (that is, if they were within 100 kb on the physical map but appeared >0.5 cM apart on the genetic map).

Choosing Candidate SNPs for Follow-Up Experimental Validation

A computer program was written to select the best SNPs for admixture mapping from the database. The program chooses SNPs that are (1) evenly spaced on the genetic map and (2) maximally informative about ancestry at each point along the genome, in the sense of having high allele frequency differentiation. Thus, it attempts to choose an optimal set of SNPs for estimating ancestry at each point in the genome.

We implemented an iterative "greedy algorithm" to choose markers in the map. The algorithm repeatedly chooses the SNP that adds the most additional information to the set that has already been identified, taking into account the fact that some information may already be provided at the site of a candidate SNP by markers already chosen for the map. For simplicity, we make the approximation that all markers in an 8-cM window centered on the candidate SNP are fully "linked for admixture" and thus can be treated as a compound locus for the purpose of ancestry inference. We also assume that more-distant markers provide no information.

To assess how much additional information is provided by a candidate SNP, we calculated the mutual information (McEliece 2002) provided about ancestry with the candidate MALD marker added in, minus the information only from nearby markers. The formula for a multimarker genotype is similar to the Rosenberg et al. (2003) equation for "informativeness for assignment." When a candidate SNP is considered alone or is >4 cM from any other SNPs, it is simply

Shannon Information Content (SIC)

$$= -\sum_{i=0}^{1} (a_{i0} + a_{i1}) \log (a_{i0} + a_{i1})$$

$$-\sum_{j=0}^{1} (a_{0j} + a_{1j}) \log (a_{0j} + a_{1j})$$

$$+\sum_{i=0}^{1} \sum_{j=0}^{1} a_{ij} \log (a_{ij}), \qquad (1)$$

with  $a_{00} = (1 - m) \times p^{\text{WA}}$ ,  $a_{01} = m \times p^{\text{EA}}$ ,  $a_{10} = (1 - m) \times (1 - p^{\text{WA}})$ , and  $a_{11} = m \times (1 - p^{\text{EA}})$ . Here,  $p^{\text{EA}}$  and  $p^{\text{WA}}$  are the SNP frequencies in European Americans and West Africans, and m is the proportion of European ancestry in African Americans, which we set to 0.21, although we found that SNP selection is not very sensitive to the choice of m. For the many SNPs in our data set for which no West African frequencies were avail-

able, we used an expectation-maximization algorithm (Dempster et al. 1977) to infer them from the African American frequencies.

The greedy algorithm described above was iteratively applied, each time choosing new markers for the map until the additional information provided by the SNP (SIC) fell below 0.035, at which point the algorithm terminated. Three additional criteria were applied for SNP selection:

- 1. Candidate SNPs were chosen for the map only if they were spaced at least 50 kb from all previously chosen ones.
- 2. The estimates of frequencies from the databases were adjusted to account for the fact that some SNPs may appear to be more attractive for admixture mapping simply because they are picked as the most extreme cases of differentiation from a database in which there is sampling fluctuation. Specifically, before applying the SNP selection algorithm, 1 was added to both the minor and major allele counts in the populations of European and African descent, to make their frequencies appear more similar. For SNPs with frequencies from less reliable pooled genotyping, the differentiation was reduced further by adding 25% to both the major and minor allele frequencies.
- 3. Finally, the estimates of frequencies were adjusted by transforming all estimates so that they were 7% closer to 0.5. This procedure encouraged the program to choose markers for the map even near the most informative SNPs, which is important because it means the map will have some power even if there are missing genotypes.

# Procedure for Experimentally Validating SNPs

All SNPs in the map were revalidated by genotyping new population samples to determine their allele frequencies. Validation of SNPs was performed at two laboratories. About half were validated at the National Cancer Institute's Laboratory of Genomic Diversity (Laboratory of Genomic Diversity Web site) in Maryland by the 5' nuclease assay (TaqMan Assays-on-Demand or Assays-by-Design SNP Genotyping Products [Applied Biosystems]) (Livak 1999), and about half were genotyped at the Broad Institute in Massachusetts by primer-oligo base extension assay resolved by MALDI-TOF mass spectrometry on a chip (MassARRAY [Sequenom]) (Tang et al. 1999). A total of 3,340 SNPs were experimentally genotyped during the validation process, although, as described below, only a subset of 3,011 were considered robust enough to be included in the complete map and presented in table A (online only).

The great majority of revalidated SNPs (2,991 of 3,340)

were genotyped in 78 European Americans (from Chicago or Baltimore), 120 sub-Saharan Africans (from Senegal, Ghana, Cameroon, or Botswana), 109 African Americans (from Chicago, Baltimore, Pittsburgh, or North Carolina), 40 Cantonese Chinese, and 29 Mexican Amerindians (table 2). For 1,136 SNPs (including 349 not studied in the main panel of samples), 78 European Americans (CEPH) and 73 sub-Saharan Africans (Beni from Nigeria) were genotyped. All samples were collected under institutional review board approval with informed consent for the genetic study at each collection site.

Identifying a Subset of SNPs That Should Be Included in MALD Mapping Panels

Validated SNPs were included in the complete 3,011-marker map if they:

- 1. were genotyped successfully in at least 20 West Africans and 20 European Americans;
- 2. were in Hardy-Weinberg equilibrium in the parental populations (*P* > .005 by *G* test summing over all European American and West African populations for which data were available and a Hardy-Weinberg statistic could be calculated);
- 3. had a minimal level of informativeness (SIC > 0.035 according to eq. [1], out of a maximum of 0.709) at the FY-null locus (also known as "Duffy"); and
- 4. were similar in frequency within continents (P > .002 in a G test in sub-Saharan African populations, excluding the more distantly related Botswana population, and P > .002 in European Americans).

# Admixture Mapping Panel Free of Historic LD

Additional SNPs with low information were eliminated until the following were satisfied:

- 5. all SNPs in the map were spaced at least 50 kb from each other, and
- 6. all SNPs in the map were not in LD with any of the other SNPs (P > .0005 not correcting for multiple hypothesis testing) in the parental populations.

## Evaluating the Power of the Map

The power to detect a disease locus through use of admixture mapping depends on two independent factors. First, there is the strength of the disease locus for which one is searching: the enrichment of one population's ancestry at that point in the genome. The accompanying article by Patterson et al. (2004 [in this issue]) explores in detail how disease model affects the power of a study. Second, there is the quality of the map: how well one is able to estimate origins of chromosomal segments from genotyping data.

To analyze the quality of the map, we used an analysis described in detail in the appendix (online only). In brief, "map power" is calculated as a quotient: the number of

Table 2
Characteristics of Samples

		POPULATION CONTRIBUTION ASSESSED BY STRUCTURE* (%)			
SAMPLE EXAMINED	n	European	African	Asian	Amerindian
European American:					
Chicago <sup>b</sup>	39	98.4	.4	.7	.5
Baltimore <sup>b</sup>	39	97.5	.4	.9	1.3
African American:					
Chicago <sup>b,c</sup>	18	18.4	80.6	.7	.3
Pittsburgh <sup>b,c</sup>	23	18.3	80.6	.6	.5
Baltimore <sup>d</sup>	45	15.9	83.2	.5	.5
North Carolina <sup>c</sup>	23	18.8	79.6	.5	1.1
African:					
Senegal <sup>e</sup>	46	2.8	95	1.6	.6
Ghana <sup>f</sup>	33	.1	99.8	.1	.1
Cameroon <sup>g</sup>	20	.1	99.8	.1	.1
Botswana <sup>h</sup>	21	1.2	98.4	.3	.1
Chinese:					
Cantonese <sup>i</sup>	40	.2	.1	98.9	.8
Amerindian:					
Mexican Zapoteci	29	4.3	.3	.5	94.8

- <sup>a</sup> The STRUCTURE analysis (Falush et al. 2003) was based on the 2,034 SNPs from the reduced 2,154-marker map that were genotyped in the samples above. The relative log likelihoods for the two-, three-, four-, five-, and six-population models in STRUCTURE (Falush et al. 2003) were -25055, -6612, 0, -756, and -667, respectively. We used a four-population model because it is most probable given the data.
- <sup>b</sup> From the Multicenter AIDS Cohort Study (Kaslow et al. 1987).
- <sup>c</sup> From the Multicenter Hemophilia Cohort Study (Goedert et al. 2002).
- <sup>d</sup> From the AIDS Link to Intravenous Experiences study (Vlahov et al. 1998).
  - <sup>e</sup> Sample from J.-L.S..
  - f Sample from S.M.W.
  - <sup>g</sup> Sample from S.A.T. (Tishkoff and Williams 2002).
  - <sup>h</sup> Sample from M.E. (Novitsky et al. 2001).
  - <sup>i</sup> Sample from Z.Y., G.T., and S.O. (unpublished data).
  - <sup>i</sup> Sample from Hollenbach et al. 2001.

samples required, given the imperfect map, divided by the number that would be necessary if one had a perfectly informative marker at every site. For example, at a point where map power is 1/3, one needs 3 times the sample size as would be necessary if one were trying to detect a locus near a marker (such as FY null) with full map power: where genotypes provide definitive information about whether patients have 0, 1, or 2 Europeanancestry alleles. In practice, map power was calculated by simulating data sets containing a disease locus and evaluating how many samples were necessary to detect it with a given level of power, compared with a perfectly informative marker such as FY null (see the appendix [online only]).

The map power calculation is somewhat overoptimistic, in that it assumes that the frequencies of alleles in parental populations are known perfectly, but inaccuracies in these measurements may in fact reduce power.

Extensive simulations were used to explore the importance of this effect. We found, for example, that a locus with a calculated map power of 70% may provide only 50% of the information of the FY null locus (see fig. 7 of Patterson et al. 2004 [in this issue]).

Data Analysis to Assess Admixture Mapping Parameters and Population Structure

The analysis from Patterson et al. (2004 [in this issue]), which is implemented in the software package AN-CESTRYMAP, was used to estimate admixture mapping parameters. The STRUCTURE program (Pritchard et al. 2000) was employed to assess the relative contributions of different populations to the multiethnic data set, using admixture LD between markers as the basis for the inference (Falush et al. 2003).

#### **Results**

A Database of SNPs for Marker Selection

The SNPs for building the admixture map came from publicly available sources (mostly in dbSNP), as well as two commercial databases (Adams et al. 2002; De La Vega et al. 2002; Applied Biosystems myScience Web site) (table 1). The Applied Biosystems database consisted of 177,781 SNPs genotyped in 46 European Americans and 45 African Americans. These data were obtained while developing the Applied Biosystems TaqMan Assays-on-Demand Genotyping Products (De La Vega et al. 2002). The Applera Genomics Initiative database consisted of 266,135 SNPs discovered in 20 European Americans and 19 African Americans by resequencing exonic and promoter regions around 23,363 annotated human genes (Adams et al. 2002). The total size of the SNP collection that we mined to obtain maximally informative markers for African American admixture mapping was ~450,000 (table 1).

Selection of MALD Marker SNPs and Experimental Validation

After each round of SNP selection and genotyping (typically 300–1,200 SNPs), the database was updated with the revised frequencies of the SNPs that were now validated, and the program was run again to select new SNPs. This iterative procedure made it possible to fill in holes in the map and to utilize new SNP allele frequencies from public and proprietary databases as they became available over the course of the project. Overall, 1,537 SNPs were genotyped only at the Laboratory of Genomic Diversity (1.3% missing data rate), and 1,770 SNPs were genotyped only at the Broad Institute (2.9% missing data rate). Of the 33 SNPs genotyped at both sites, 61 discrepancies were observed out of 11,847 ge-

notypes obtained at least in duplicate (0.51%). This indicates an average error rate of ~0.26%.

Selection of 3,011 Markers with High Frequency Differentiation across Populations


From the 3,340 experimentally revalidated SNPs, we selected 3,011 that are maximally informative for admixture mapping (table 1; also see table A [online only], a tab-delimited ASCII file that can be imported into a spreadsheet). The median allele frequency difference between West Africans and European Americans is 56%, and the median SIC according to equation (1) is 25% of the maximum. The allele frequency estimates obtained by our revalidation genotyping in each ethnic group, the map positions, and the flanking sequences for the SNPs are all presented in table A (online only). All markers in this map are freely and publicly available without restriction, and genotypes are available on request. Chromosomal maps, figures showing the positions of each of the MALD markers in the genome, are available from the Laboratory of Genomic Diversity Web site.

Power of 2,154 Widely Spaced Markers for Admixture Mapping

We further selected 2,154 SNPs that are optimized for current admixture mapping analysis strategies (e.g., Falush et al. 2003; Patterson et al. 2004 [in this issue]), in the sense of having no LD among them in the parental African and European populations. We calculated the power of this panel for admixture mapping, where map power is defined (as above) as the information provided by the map about ancestry at a given point in the genome, compared with what would be obtained from genotyping a 100% informative marker that perfectly differentiates between populations.

When we assess the power in African Americans, the average map power for a random position in the genome is 71%  $\pm$  9% of the maximum (mean  $\pm$  SD) (figs. 1 and 2). The power for 50%-50% mixtures of Africans-Amerindians is 66%  $\pm$  11%, for Europeans-Amerindians is 30%  $\pm$  11%, and for Europeans-East Asians is 36%  $\pm$  11%. The fact that East Asians are slightly more distinctive than Amerindians as compared with Europeans may reflect a small amount of confounding European admixture among the Amerindian samples (table 2).

Figure 2 presents the distribution of map power across the genome. Because the average information content extracted from African American samples is 71%, at an average locus one needs to study 1/0.71 = 1.4 times as many samples to detect disease genes as would be necessary if one had full ancestry information. Uncertainties in the frequencies in the parental populations, however, mean that, in practice, these estimates are overoptimistic



**Figure 1** Power of the individual 2,154 MALD markers (*white bars*), as a fraction of the maximum (power is calculated by eq. [1]). Power increases strikingly when the methods described by Patterson et al. (2004 [in this issue]) are used to combine data from multiple, closely linked markers (*black bars*).

(see the "Methods" section and Patterson et al. 2004 [in this issue]). The true information content is ~50%, comparable to the power of standard linkage maps (M. Daly, personal communication). Admixture genome scans using the present 2,154-marker map should therefore have double the sample size than would be necessary with a "perfect admixture map" in which every marker was as maximally differentiated as the *FY* null allele between the parental African and European populations. Calculations for such a "perfect admixture map," for various disease models, are presented in the article by Patterson et al. (2004 [in this issue]). Power would be improved if extra information were incorporated from the full 3,011-marker map.

# Subsets of SNPs for Estimating Population Ancestry

A subset of MALD markers can be genotyped to estimate the proportion of ancestry for each individual in a study (Parra et al. 1998). Genotyping such panels of markers allows researchers to search for evidence of genetic risk for a disease being higher in one ancestral population than another. For example, prostate cancer (Kittles et al. 2002), BMI (Fernandez et al. 2003), lupus (Molokhia et al. 2003), and several other traits (Halder and Shriver 2003) have all been genetically associated with the proportion of African ancestry. Estimating ancestry proportions in individuals is also useful for controlling for population stratification—systematic differences in ancestry between cases and controls—which can cause false positives in association studies (Pfaff et al. 2002; Hoggart et al. 2003; Freedman et al. 2004).


Table B (online only), a tab-delimited ASCII file that

can be imported into a spreadsheet, provides lists of 100 SNPs spaced by at least 25 cM that are optimal for distinguishing four different mixtures and for making precise ancestry estimates. The average differences in allele frequencies are 78% (for African/European mixture), 85% (for African/American Indian mixture), 56% (for European/American Indian mixture), and 57% (for European/East Asian mixture).


Estimates of Admixture Mapping Parameters from the Genotyping Data in this Study


The ANCESTRYMAP software described in the accompanying article by Patterson et al. (2004 [in this issue]) was used to estimate parameters relevant to admixture mapping. First, the range of proportions of European ancestry was estimated for the 109 African American samples in this study (fig 3A). The range of estimates is  $20\% \pm 8\%$  (mean  $\pm$  SD), slightly lower than the estimate of  $21\% \pm 11\%$  for 718 unrelated samples from the study by Patterson et al. (2004 [in this issue]). We note that 95% of the samples in this study are estimated to have 10%–90% European ancestry, in the range of maximal power for admixture mapping (Patterson et al. 2004 [in this issue]).

Second, we estimated the number of generations since admixture for each individual (fig. 3B). Since gene flow between European Americans and African Americans has occurred over many generations, the estimated number of generations since admixture should, in fact, be interpreted as an average across a person's different lineages (Stephens et al. 1994; Pfaff et al. 2001). We estimate  $6.3 \pm 1.1$  generations since admixture for these 109



**Figure 2** Power of the 2,154-marker map as a fraction of what would be expected if there was full information about ancestry available at every point (e.g., nearly complete information [a value of 1 on the Y-axis] is available at Duffy on chromosome 1, indicated by a star). The black line is the power of the African American map under the assumption of an average of six generations since admixture (the power would be lower for individuals with more generations since admixture). We were also able to roughly estimate the quality of the map for studies involving Amerindian and East Asian mixtures under the assumption of six generations since admixture, although these estimates are less reliable because the sample sizes were smaller.






**Figure 3** A, Distribution of percentage of European ancestry  $(M_i)$  in 109 African American samples genotyped at 2,154 MALD markers (mean  $\pm$  SD = 20%  $\pm$  8%). B, Distribution of estimated number of generations since admixture  $(\lambda_i)$  for 109 African Americans (mean  $\pm$  SD = 6.3  $\pm$  1.1). All estimates are generated by the ANCESTRYMAP software from the accompanying article by Patterson et al. (2004 [in this issue]). We emphasize that the number of "generations since admixture" is an average across a person's lineages, since mixing between Africans and Europeans has occurred over many generations.

samples, which is similar to the result of  $6.0 \pm 1.6$  for the 718 samples studied by Patterson et al. (2004 [in this issue]). We used this to estimate the probability of no recombination since admixture between a disease locus and neighboring sites; that is, the extent of admixture LD in the African American population (fig. 4). A peak of association is expected to fall to half its maximum LOD score within 11 cM of a disease locus, consistent with previous estimates of 10–20 cM for strong admixture LD in African Americans (Parra et al. 1998; Lautenberger et al. 2000; Collins-Schramm et al. 2003; Falush et al. 2003; Patterson et al. 2004 [in this issue]).

Third, we applied the Patterson et al. (2004 [in this

issue]) analytic approach to chromosome 1 for 5 African American individuals, each with different percentages of European ancestry, selected from the 109 in this study. The analysis demonstrates clear transitions between segments of 0, 1, or 2 European alleles, with stretches of European and African ancestry extending for tens of megabases (fig. 5). To screen for disease genes on the basis of such data, the Patterson et al. (2004 [in this issue]) ANCESTRYMAP software combines these estimates across many individuals, searching for regions where the average proportion of African ancestry is higher (or lower) than the genomewide average.

Fourth and finally, application of the ANCESTRY-



**Figure 4** Predicted probability of no recombination having occurred since admixture between a disease locus and a nearby marker locus, predicting the shape of a peak of association in an African American admixture study. The analysis was based on the distribution of the estimated number of generations since admixture  $(\lambda_i)$  values estimated from 109 African Americans (fig. 3*B*). We present the probability of a crossover between ancestry segments, as a function of the distance between a disease locus and mapping marker. At 4.5 cM, we expect the strength of association to drop to 75% of its maximum (measured as LOD or log of the *P* value). At 11 cM and 23 cM, the power drops to 50% and 25% of its maximum, respectively.

MAP software allowed us to assess how closely the West African and European American populations corresponded to the true parental populations for African Americans. The software can estimate a parameter  $\tau_{\rm E}$ for Europeans and  $\tau_A$  for Africans, indicating how much drift has occurred between the parental population and actual European American and West African samples that have been genotyped. An interpretation of  $\tau_{\rm E}$  and  $au_{\rm A}$  is that the true frequencies in the parental populations of African Americans are as close to those in the European American and West African controls as would be expected if the control sample frequencies were obtained by sampling  $au_{\scriptscriptstyle E}$  alleles and  $au_{\scriptscriptstyle A}$  alleles from the ancestral African American populations (e.g., Nicholson et al. 2002). The West Africans and European Americans are fairly close to the parental populations ( $\tau_E = 135$ ;  $\tau_{\rm A} = 242$ ). For example, this means that if the true allele frequency of a SNP in the African ancestors of an African American sample was 30%, its frequency in the West African samples studied here is 95% likely to be in the range of 27%-33%. This is encouraging for potential applications of admixture mapping, but not surprising. As has been previously observed (Collins-Schramm et al. 2003), there is remarkable similarity in allele frequencies across all of West Africa, which is thought to be the source population for African Americans (perhaps because of the Bantu expansion across West Africa within the past 5,000 years). In addition, the 2,154 MALD markers chosen for the map were specifically selected

not to differ strikingly in frequency across West African or European American populations, to minimize withincontinent allele frequency divergences.


Analysis of Population Structure from the Genotyping Data

The STRUCTURE program (Pritchard et al. 2000; Falush et al. 2003), which clusters individuals into populations based on characteristic LD patterns between linked and unlinked loci, was used to assess population differentiation on the basis of the genotyping data from the main panel of 376 samples (table 2). The STRUC-TURE analysis strongly supports the partition into four ancestral populations, corresponding to West Africans, Europeans, American Indians, and East Asians (table 2). The four African American populations were estimated to have 16%-19% European ancestry, consistent with the estimates of Parra et al. (1998). Modest admixture is also inferred for the other populations (e.g., European admixture in Amerindians and European admixture in Senegal and Botswana), although STRUCTURE does not provide statistical confidence about the presence of admixture.

## Discussion

We have developed a high-density admixture map for studies in African Americans. This map contains 3,011 highly differentiated SNPs that are about five times more informative, on average, than a random microsatellite (Smith et al. 2001; Rosenberg et al. 2003). In the accompanying article (Patterson et al. 2004 [in this issue]), we present a method that allows for efficient use of this map. Other analysis methods, including those of McKeigue (1997, 1998) and Hoggart et al. (2003), as well as straightforward association tests (Chakraborty and Weiss 1988; Stephens et al. 1994), will also benefit from the admixture map. Diseases with strikingly different risks in populations of African and European descent (table 3) are particularly promising for admixture mapping in African Americans, as long as the difference in risk has a genetic underpinning and is not entirely due to environmental influences.

Comparable resources for admixture mapping in Hispanic populations or in Asian admixed groups are not yet available. Candidate SNPs have been identified by Parra et al. (1998) and Collins-Schramm et al. (2004), and our map contains several hundred markers that appear to be highly informative for both Hispanic and Asian admixture mapping (fig. 2). To build dense maps comparable to the one presented here for African Americans, it will be necessary to first mine large databases, such as those being developed in the international haplotype map project (International HapMap Consortium



**Figure 5** Estimates of ancestry along chromosome 1 for five African American samples, estimated by use of the Patterson et al. (2004 [in this issue]) ANCESTRYMAP software. The positions of the 169 markers in the map on chromosome 1 that were used for this inference are indicated by hash marks (inferred European chromosome segments are indicated by black bars). Sharp transitions between segments of 0, 1, or 2 European alleles are clear from the analysis, indicating the high resolution of the map.

Table 3
Candidate Diseases for Admixture Mapping in African Americans

Disease	Relative Risk (95% CI)	Reference
Hepatitis C clearance	.19 (.10–.38)	Thomas et al. 2000
HIV vertical transmission	.30 (.1090)	Tess et al. 1998
Multiple sclerosis	.45 (.3555)	Kurtzke et al. 1979
Lung cancer	1.48 (1.38–1.67)	Davey Smith et al. 1998
Stroke	1.57 (1.27–1.94)	Davey Smith et al. 1998
End-stage renal disease	1.87 (1.47-2.39)	Klag et al. 1997
Intracranial hemorrhage	2.10 (1.44-3.06)	Davey Smith et al. 1998
Focal segmental glomerulosclerosis	2.43 (1.09–5.45)	Lopes et al. 1999
Prostate cancer	2.73 (2.13-3.52)	Davey Smith et al. 1998
Hypertensive heart disease	2.80 (2.03-3.86)	Davey Smith et al. 1998
Myeloma	3.14 (2.00-4.93)	Davey Smith et al. 1998

NOTE.—Relative risks given are for African Americans versus European Americans. Admixture mapping may also work for diseases with small incidence differences between African Americans and European Americans, because the risk may be differently distributed over loci. However, these should not be the first diseases to which the method is applied.

2003), and then to validate candidate SNPs in a new and diverse sample set representative of the ancestral populations of Hispanic American and admixed Asian populations. The resulting marker maps will provide a powerful resource for admixture mapping of high-incidence disease-causing alleles in these populations.

The map of MALD markers that we have described and the methods presented in the accompanying article (Patterson et al. 2004 [in this issue]) now make highdensity admixture mapping in African Americans practical. However, no new disease gene has ever been identified by admixture mapping, so validation of the approach will require the study of large collections of unrelated patients affected by disease. Only a few thousand markers need to be genotyped to perform a powerful admixture mapping study, and, thus, a wholegenome scan is practical with current technologies. Admixture mapping can, in theory, localize disease variants that differ strikingly in frequency across populations, to within 5–10 cM (fig. 4). This is a finer scale than linkage mapping but much rougher than haplotype-based association mapping. We conclude that admixture mapping provides a major new practical addition to the approaches available for discovering novel genes underlying the development of complex diseases.

# Acknowledgments

We are grateful to the many individuals whose DNA samples were used in this study and to Robert Ferrell for sharing the Beni samples from Nigeria. Technical help came from Ellen Frazier, Kui Gong, Shanise Hill, Guo Kui Pei, Carolyn Whistler, Lewis Wogan, Xiaoqing You, and Janet Ziegle. We thank Mark Adams, Michele Cargill, Jean-Paul Chretien, Josef Coresh, Michael Dean, Allen Kane, Michael Klag, and Eric Lander for contributing important insights or data. N.P. is supported by a National Institutes of Health (NIH) K-01

award (grant HG002758-01), P.L.D. is supported by National Institute of Neurological Disorders and Stroke grant K08 NS046341 and is the William C. Fowler Scholar in multiple sclerosis research, and J.H.M., K.P., and S.M.W. are supported by NIH grant HL-65234. D.R. is the recipient of a Career Development Award from the Burroughs Wellcome Fund. D.A. is a Burroughs-Wellcome Fund Clinical Scholar in Translational Research, as well as a Charles E. Culpeper Medical Scholar. The experimental work at the NCI was made possible by reagents contributed by Applied Biosystems and was funded by an NIH/NCI contract (NO1-CO-12400). The experimental work at the Broad Institute was made possible by subcontract U19-AI50864 from the NIH/National Institute of Allergy and Infectious Diseases, a grant from the Wadsworth Foundation, and a grant from the National Multiple Sclerosis Society (to D.R. and D.A.H.). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.

# **Electronic-Database Information**

The URLs for data presented herein are as follows:

Applied Biosystems myScience Web site, http://myscience .appliedbiosystems.com

dbSNP, http://www.ncbi.nlm.nih.gov/SNP/

Laboratory of Genomic Diversity, http://home.ncifcrf.gov/ccr/lgd/human\_genome/mald/index\_n.asp (for figures showing positions of map SNPs in the genome)

SNP Consortium, http://snp.cshl.org/allele\_frequency\_project/ University of Washington Fred Hutchinson Cancer Research Center (UW-FHCRC) Variation Discovery Resource, http:// pga.gs.washington.edu/

# References

Adams MD, Cargill MA, Spier EG, De La Vega FM, Olson SJ, White TJ, Sninsky JJ, Gilbert DA, Hunkapiller MW

- (2002) Applied genomics: exploring functional variation and gene expression. Am J Hum Genet Suppl 71:203
- Briscoe D, Stephens JC, O'Brien SJ (1994) Linkage disequilibrium in admixed populations: applications in gene mapping. J Hered 85:59–63
- Carlson CS, Eberle MA, Rieder MJ, Smith JD, Kruglyak L, Nickerson DA (2003) Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat Genet 33:518–521
- Chakraborty R, Weiss KM (1988) Admixture as a tool for finding linked genes and detecting that difference from allelic association between loci. Proc Natl Acad Sci USA 85:9119–9123
- Chen M-H, Shao Q-M, Ibrahim JG (2000) Monte Carlo methods in Bayesian computation. Springer, New York
- Collins-Schramm HE, Chima B, Morii T, Wah K, Figueroa Y, Criswell LA, Hanson RL, Knowler WC, Silva G, Belmont JW, Seldin MF (2004) Mexican American ancestry-informative markers: examination of population structure and marker characteristics in European Americans, Mexican Americans, Amerindians and Asians. Hum Genet 114:263–271
- Collins-Schramm HE, Chima B, Operario DJ, Criswell LA, Seldin MF (2003) Markers informative for ancestry demonstrate consistent megabase-length linkage disequilibrium in the African American population. Hum Genet 113:211– 219
- Davey Smith G, Neaton JD, Wentworth D, Stamler R, Stamler J (1998) Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT. Lancet 351:934–939
- De La Vega FM, Dailey D, Ziegle J, Williams J, Madden D, Gilbert DA (2002) New generation pharmacogenomic tools: a SNP linkage disequilibrium map, validated SNP assay resource, and high-throughput instrumentation system for large-scale genetic studies. Biotechniques Suppl 32:S48–S54
- Dempster AP, Laird NM, Rubin DB (1977) Maximum likelihood from incomplete data via the EM algorithm. J R Stat Soc Ser B 39:1–38
- Falush D, Stephens M, Pritchard JK (2003) Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 164:1567–1587
- Fernandez JR, Shriver MD, Beasley TM, Rafla-Demetrious N, Parra E, Albu J, Nicklas B, Ryan AS, McKeigue PM, Hoggart CL, Weinsier RL, Allison DB (2003) Association of African genetic admixture with resting metabolic rate and obesity among women. Obes Res 11:904–911
- Freedman ML, Reich D, Penney KL, McDonald GJ, Mignault AA, Patterson N, Gabriel SB, Topol EJ, Smoller JW, Pato CN, Pato MT, Petryshen TL, Kolonel LN, Lander ES, Sklar P, Henderson B, Hirschhorn JN, Altshuler D (2004) Assessing the impact of population stratification on genetic association studies. Nat Genet 36:388–393
- Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of haplotype blocks in the human genome. Science 296: 2225–2229
- Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De

- Moerloose P, White GC 2nd, Angiolillo AL, Luban NL, Sherman KE, Manco-Johnson M, Preiss L, Leissinger C, Kessler CM, Cohen AR, DiMichele D, Hilgartner MW, Aledort LM, Kroner BL, Rosenberg PS, Hatzakis A (2002) End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 100:1584–1589
- Halder I, Shriver MD (2003) Measuring and using admixture to study the genetics of complex disease. Hum Genomics 1: 52–62
- Hoggart CJ, Parra EJ, Shriver MD, Bonilla C, Kittles RA, Clayton DG, McKeigue PM (2003) Control of confounding of genetic associations in stratified populations. Am J Hum Genet 72:1492–1504
- Hollenbach JA, Thomson G, Cao K, Fernandez-Vina M, Erlich
   HA, Bugawan TL, Winkler C, Winter M, Klitz W (2001)
   HLA diversity, differentiation, and haplotype evolution in
   Mesoamerican Natives. Hum Immunol 62:378–390
- International HapMap Consortium (2003) The International HapMap Project. Nature 426:789–796
- Kaslow RA, Ostrow DG, Detels R, Phair JP, Polk BF, Rinaldo CR Jr (1987) The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 126:310–318
- Kittles RA, Chen W, Panguluri RK, Ahaghotu C, Jackson A, Adebamowo CA, Griffin R, Williams T, Ukoli F, Adams-Campbell L, Kwagyan J, Isaacs W, Freeman V, Dunston GM (2002) CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 110:553–560
- Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J (1997) End-stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 277: 1293–1298
- Kong A, Gudbjartsson DF, Sainz J, Jonsdottir GM, Gudjonsson SA, Richardsson B, Sigurdardottir S, Barnard J, Hallbeck B, Masson G, Shlien A, Palsson ST, Frigge ML, Thorgeirsson TE, Gulcher JR, Stefansson K (2002) A high-resolution recombination map of the human genome. Nat Genet 31:241–247
- Kurtzke JF, Beebe GW, Norman JE Jr (1979) Epidemiology of multiple sclerosis in U. S. veterans. 1. Race, sex and geographic distribution. Neurology 29:1228–1235
- Lautenberger JA, Stephens JC, O'Brien SJ, Smith MW (2000) Significant admixture linkage disequilibrium across 30 cM around the FY locus in African Americans. Am J Hum Genet 66:969–978
- Lewontin RC (1972) The apportionment of human diversity. In: Dobzhansky T, Hecht MK, Steere WC (eds) Evolutionary Biology 6. Appleton-Century-Crofts, New York, pp 381–398
- Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 14:143–149
- Lopes AA, Martinelli RP, Silveira MA, Rocha H (1999) Racial differences between patients with focal segmental glomerulosclerosis and membranoproliferative glomerulonephritis from the State of Bahia. Rev Assoc Med Bras 45:115–120
- McEliece R (2002) The theory of information and coding. Encyclopaedia of mathematics and its applications (second edition). Cambridge University Press, Cambridge, United Kingdom

- McKeigue PM (1997) Mapping genes underlying ethnic differences in disease risk by linkage disequilibrium in recently admixed populations. Am J Hum Genet 60:188–196
- ——— (1998) Mapping genes that underlie ethnic differences in disease risk: methods for detecting linkage in admixed populations, by conditioning on parental admixture. Am J Hum Genet 63:241–251
- McKeigue PM, Carpenter JR, Parra EJ, Shriver MD (2000) Estimation of admixture and detection of linkage in admixed populations by a Bayesian approach: application to African-American populations. Ann Hum Genet 64:171–186
- Molokhia M, Hoggart C, Patrick AL, Shriver M, Parra E, Ye J, Silman AJ, McKeigue PM (2003) Relation of risk of systemic lupus erythematosus to west African admixture in a Caribbean population. Hum Genet 112:310–318.
- Nei M, Roychoudhury AK (1982) Genetic relationship and evolution of human races. Evol Biol 14:1–59
- Nicholson G, Smith AV, Jónsson F, Gústafson Ó, Stefansson K, Donnelly P (2002) Assessing population differentiation and isolation from single-nucleotide polymorphism data. J R Stat Soc Ser B 64:695–715
- Novitsky V, Rybak N, McLane MF, Gilbert P, Chigwedere P, Klein I, Gaolekwe S, Chang SY, Peter T, Thior I, Ndung'u T, Vannberg F, Foley BT, Marlink R, Lee TH, Essex M (2001) Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 75:9210–9228
- Parra EJ, Marcini A, Akey J, Martinson J, Batzer MA, Cooper R, Forrester T, Allison DB, Deka R, Ferrell RE, Shriver MD (1998) Estimating African American admixture proportions by use of population-specific alleles. Am J Hum Genet 63: 1839–1851
- Patterson N, Hattangadi N, Lane B, Lohmueller KE, Hafler DA, Oksenberg JR, Hauser SL, Smith MW, O'Brien SJ, Altshuler A, Daly M, Reich D (2004) Methods for high-density admixture mapping of disease genes. Am J Hum Genet 74: 979–1000 (in this issue)
- Pfaff CL, Kittles RA, Shriver MD (2002) Adjusting for population structure in admixed populations. Genet Epidemiol 22:196–201
- Pfaff CL, Parra EJ, Bonilla C, Hiester K, McKeigue PM, Kamboh MI, Hutchinson RG, Ferrell RE, Boerwinkle E, Shriver MD (2001) Population structure in admixed populations:

- effect of admixture dynamics on the pattern of linkage disequilibrium. Am J Hum Genet 68:198–207
- Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155: 945–959
- Reich DE, Gabriel SB, Altshuler D (2003) Quality and completeness of SNP databases. Nat Genet 33:457–458
- Risch N (1992) Mapping genes for association studies with recently admixed populations. Am J Hum Genet Suppl 51: A13
- Rosenberg NA, Li LM, Ward R, Pritchard JK (2003) Informativeness of genetic markers for inference of ancestry. Am J Hum Genet 73:1402–1422
- Smith MW, Lautenberger JA, Shin HD, Chretien JP, Shrestha S, Gilbert DA, O'Brien SJ (2001) Markers for mapping by admixture linkage disequilibrium in African American and Hispanic populations. Am J Hum Genet 69:1080–1094
- Stephens JC, Briscoe D, O'Brien SJ (1994) Mapping by admixture linkage disequilibrium in human populations: limits and guidelines. Am J Hum Genet 55:809–824
- Tang K, Fu DJ, Julien D, Braun A, Cantor CR, Koster H (1999)Chip-based genotyping by mass spectrometry. Proc Natl Acad Sci USA 96:10016–10020
- Tess BH, Rodrigues LC, Newell ML, Dunn DT, Lago TD (1998) Breastfeeding, genetic, obstetric and other risk factors associated with mother-to-child transmission of HIV-1 in Sao Paulo State, Brazil. AIDS 12:513–520
- Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D (2000) The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284:450–456
- Tishkoff SA, Williams SM (2002) Genetic analysis of African populations: human evolution and complex disease. Nat Rev Genet 3:611–621
- Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, Lyles CM, Nelson KE, Smith D, Holmberg S, Farzadegan H (1998) Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4<sup>+</sup> cell count. JAMA 279:35–40
- Zheng C, Elston RC (1999) Multipoint linkage disequilibrium mapping with particular reference to the African-American population. Genet Epidemiol 17:79–101